Elicera Therapeutics AB (publ) announced that it has received a Communication EPC (Notice of Allowance) from the European Patent Office in its European patent application relating to the use of the iTANK[TM] technology in CAR T-cell therapies. The Communication means that the European Patent Office intends to grant the European patent application after the completion of certain formal steps. Once granted, the patent can be kept in force until 2036.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.065 SEK | +8.67% | +13.30% | -76.64% |
03-28 | Elicera Therapeutics AB Announces Director Changes | CI |
03-06 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.64% | 3.21M | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |
- Stock Market
- Equities
- ELIC Stock
- News Elicera Therapeutics AB
- Elicera Therapeutics AB Receives Notice of Allowance for European Patent Protecting the iTANK